ESCC

This phase 2 trial tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery in 26 patients with locally advanced esophageal cancer. The goal is to see if this approach can completely eliminate cancer cells in the removed tis…

This phase II trial tests a combination of three drugs (adebrelimab, nimotuzumab, and chemotherapy) given before surgery to 22 patients with resectable esophageal squamous cell carcinoma. The main goal is to see if the cancer disappears completely after treatment. If it works, th…

This study tests a new combination of drugs (QL1706 plus chemotherapy) as the first treatment for people with advanced or spreading esophageal cancer. About 50 adults who have not had prior treatment will receive the combo to see if it shrinks tumors and how long it keeps the can…

This study tests a chemotherapy drug (TAS-102) combined with radiation in people aged 65-85 with advanced esophageal cancer. The goal is to find the safest dose and see if the combination helps control the cancer and improves survival. About 45 participants will take part across …

This study tests a combination of two drugs, SHR-1701 and liposomal irinotecan, in 33 adults with esophageal squamous cell carcinoma who have already received immunotherapy. The goal is to see if the combo can shrink tumors or stop them from growing. Participants will receive the…

This study tests a drug called adebrelimab combined with chemotherapy before deciding on surgery for people with a certain type of esophageal cancer. About 200 participants will receive the treatment first. If the cancer disappears completely on scans, they will be randomly assig…

This study tests a new combination of three drugs—becotatug vedotin, tislelizumab, and chemotherapy—for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The goal is to see if adding the targeted drug becotatug vedotin to standard im…